Skip to main content
main-content
Top

27-07-2017 | Head and neck cancers | Article

Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas

Journal:
Journal of Cancer Research and Clinical Oncology

Authors: Huaising C. Ko, Paul M. Harari, Ryan M. Sacotte, Shuai Chen, Aaron M. Wieland, Menggang Yu, Andrew M. Baschnagel, Justine Y. Bruce, Randall J. Kimple, Matthew E. Witek

Publisher: Springer Berlin Heidelberg

Abstract

We examined overall survival in a large cohort of patients with human papillomavirus (HPV)-positive and HPV-negative non-oropharyngeal squamous cell carcinoma of the head and neck (non-OPSCC).
Patients diagnosed with non-OPSCC and known HPV status were identified in the National Cancer Database (NCDB). Multivariate logistic regression was applied to examine factors associated with HPV status. Multivariate analysis was utilized to determine factors correlated with overall survival. Propensity score-weighted Kaplan–Meier estimation was used to adjust for confounders in survival analyses. Multiple imputation method was used for sensitivity analysis.
We identified 19,993 non-OPSCC patients with 5070 being positive for HPV in the NCDB. Median follow-up was 23.5 months. HPV-positive patients were more commonly male, white, with a lower comorbidity index score, presenting with T-stage <2, and N-stage ≥1. Unadjusted 3-year overall survival was 62% and 80% for HPV-negative and HPV-positive patients, respectively (p < 0.0001). On multivariate analysis, mortality was reduced for HPV-positive patients with early stage (HR = 0.68) and locally advanced disease (HR = 0.46). Adjusted 3-year overall survival was 65% for HPV-negative and 76% for HPV-positive patients (p < 0.0001). The survival advantage of HPV was maintained in all subsites and robust on sensitivity analysis.
Patients with HPV-positive non-OPSCC exhibit similar characteristics as HPV-positive OPSCC. Overall survival was significantly higher for patients with HPV-positive versus HPV-negative non-OPSCC. These data reveal that HPV-positive non-OPSCC represent a favorable cohort that warrants recognition in the design of future clinical trial investigation.

Please log in to get access to this content

Related topics